NO20022525L - Farmasöytiske formuleringer inneholdende zolmitriptan - Google Patents

Farmasöytiske formuleringer inneholdende zolmitriptan

Info

Publication number: NO20022525L
Authority: NO; Norway
Prior art keywords: pharmaceutical formulations; formulations containing; zolmitriptan; containing zolmitriptan; formulation
Prior art date: 1999-12-03

Application number

NO20022525A

Other languages

English (en)

Other versions

NO20022525D0 (no

NO322119B1 (no

Inventor

Alan Roy Dearn

Sarah Louise Williamson

Simon John Summers

Trevor John Coomber

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-03

Filing date

2002-05-28

Publication date

2002-05-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022525(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-05-28 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2002-05-28 Publication of NO20022525D0 publication Critical patent/NO20022525D0/no

2002-05-28 Publication of NO20022525L publication Critical patent/NO20022525L/no

2006-08-14 Publication of NO322119B1 publication Critical patent/NO322119B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20022525A 1999-12-03 2002-05-28 Farmasøytiske formuleringer inneholdende zolmitriptan for intranasal administrering NO322119B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9928578.5A GB9928578D0 (en)	1999-12-03	1999-12-03	Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en)	1999-12-03	2000-11-28	Pharmaceutical formulations containing zolmitriptan

Publications (3)

Publication Number	Publication Date
NO20022525D0 NO20022525D0 (no)	2002-05-28
NO20022525L true NO20022525L (no)	2002-05-28
NO322119B1 NO322119B1 (no)	2006-08-14

Family

ID=10865629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022525A NO322119B1 (no)	1999-12-03	2002-05-28	Farmasøytiske formuleringer inneholdende zolmitriptan for intranasal administrering

Country Status (28)

Country	Link
US (2)	US6750237B1 (no)
EP (1)	EP1237551B1 (no)
JP (1)	JP2003515559A (no)
KR (1)	KR100670092B1 (no)
CN (1)	CN1222287C (no)
AT (1)	ATE291914T1 (no)
AU (1)	AU778092B2 (no)
BR (1)	BRPI0016138B8 (no)
CA (1)	CA2392050C (no)
CZ (1)	CZ301528B6 (no)
DE (1)	DE60019162T2 (no)
EE (1)	EE05305B1 (no)
ES (1)	ES2236001T3 (no)
GB (2)	GB9928578D0 (no)
HK (3)	HK1048442B (no)
HU (1)	HU229458B1 (no)
IL (2)	IL149578A0 (no)
IS (1)	IS2135B (no)
MX (1)	MXPA02005319A (no)
NO (1)	NO322119B1 (no)
NZ (1)	NZ518862A (no)
PL (1)	PL200679B1 (no)
PT (1)	PT1237551E (no)
RU (1)	RU2255736C2 (no)
SK (1)	SK287228B6 (no)
UA (1)	UA75059C2 (no)
WO (1)	WO2001039772A1 (no)
ZA (1)	ZA200203704B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8465468B1 (en)	2000-06-29	2013-06-18	Becton, Dickinson And Company	Intradermal delivery of substances
GB9928578D0 (en) *	1999-12-03	2000-02-02	Zeneca Ltd	Pharmaceutical formulations
SE0102855D0 (sv) *	2001-08-27	2001-08-27	Astrazeneca Ab	Method of treatment
US20050256182A1 (en) *	2004-05-11	2005-11-17	Sutter Diane E	Formulations of anti-pain agents and methods of using the same
WO2005115345A1 (en) *	2004-05-28	2005-12-08	Imaginot Pty Ltd	Oral therapeutic compound delivery system
US8216610B2 (en)	2004-05-28	2012-07-10	Imaginot Pty Ltd.	Oral paracetamol formulations
EP1812428A2 (en) *	2004-11-19	2007-08-01	Teva Pharmaceutical Industries Ltd	Zolmitriptan crystal forms
CN100341504C (zh) *	2004-12-01	2007-10-10	鲁南制药集团股份有限公司	佐米曲普坦速释制剂
EP3263117A1 (en) *	2005-11-28	2018-01-03	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
WO2008016678A2 (en) *	2006-08-01	2008-02-07	Sunesis Pharmaceuticals, Inc.	Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
BRPI0715579A2 (pt) *	2006-10-19	2015-05-26	Auspex Pharmaceuticals Inc	"composto, composição farmacêutica e uso de um composto"
KR101517415B1 (ko) *	2008-05-14	2015-05-07	에스케이바이오팜 주식회사	난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
AU2011316225B2 (en)	2010-10-15	2016-05-19	Contera Pharma Aps	Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (ja) *	2012-02-09	2017-04-26	久光製薬株式会社	マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
HUE037732T2 (hu)	2012-04-18	2018-09-28	Contera Pharma Aps	A mozgászavarok fejlett kezelésére alkalmas, szájon át szedhetõ gyógyszerészeti készítmény
US11554229B2 (en)	2013-03-26	2023-01-17	OptiNose Inc.	Nasal administration
KR101624049B1 (ko)	2014-10-29	2016-05-24	연세대학교 산학협력단	사카린을 이용한 용해도를 증가시킨 약제학적 조성물
CN108135916B (zh) *	2015-06-19	2022-01-28	北京科辉智药生物科技有限责任公司	手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017122161A1 (en)	2016-01-15	2017-07-20	Cadila Healthcare Limited	An intranasal composition comprising 5ht1b/1d receptor agonists
EP3481385A1 (en)	2016-07-11	2019-05-15	Contera Pharma APS	Pulsatile drug delivery system for treating morning akinesia
WO2019126766A1 (en) *	2017-12-21	2019-06-27	Taiwan Liposome Co., Ltd.	Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en)	2020-04-15	2021-10-21	Farzana Shaheen	Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ238424A (en) *	1990-06-07	1993-12-23	Wellcome Found	3,5-substituted indole derivatives; medicaments and preparatory processes.
JP2000505090A (ja) *	1996-07-11	2000-04-25	ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ	インドール選択的セロトニンアゴニストを含む包接錯体
GB2315673A (en) *	1996-08-01	1998-02-11	Merck & Co Inc	Treatment of migraine
DE59804534D1 (de) *	1997-02-05	2002-07-25	Jago Res Ag Muttenz	Medizinische aerosolformulierungen
GB9928578D0 (en) *	1999-12-03	2000-02-02	Zeneca Ltd	Pharmaceutical formulations

1999
- 1999-12-03 GB GBGB9928578.5A patent/GB9928578D0/en not_active Ceased
2000
- 2000-11-28 BR BRPI0016138A patent/BRPI0016138B8/pt not_active IP Right Cessation
- 2000-11-28 IL IL14957800A patent/IL149578A0/xx active IP Right Grant
- 2000-11-28 ES ES00979765T patent/ES2236001T3/es not_active Expired - Lifetime
- 2000-11-28 DE DE60019162T patent/DE60019162T2/de not_active Expired - Lifetime
- 2000-11-28 SK SK753-2002A patent/SK287228B6/sk not_active IP Right Cessation
- 2000-11-28 CN CNB008163820A patent/CN1222287C/zh not_active Expired - Lifetime
- 2000-11-28 AU AU17157/01A patent/AU778092B2/en not_active Expired
- 2000-11-28 UA UA2002075443A patent/UA75059C2/uk unknown
- 2000-11-28 CZ CZ20021901A patent/CZ301528B6/cs not_active IP Right Cessation
- 2000-11-28 PL PL357597A patent/PL200679B1/pl unknown
- 2000-11-28 EP EP00979765A patent/EP1237551B1/en not_active Expired - Lifetime
- 2000-11-28 AT AT00979765T patent/ATE291914T1/de active
- 2000-11-28 KR KR1020027006849A patent/KR100670092B1/ko active IP Right Grant
- 2000-11-28 NZ NZ518862A patent/NZ518862A/en not_active IP Right Cessation
- 2000-11-28 GB GB0214845A patent/GB2373726B/en not_active Expired - Lifetime
- 2000-11-28 RU RU2002117649/15A patent/RU2255736C2/ru active
- 2000-11-28 EE EEP200200283A patent/EE05305B1/xx unknown
- 2000-11-28 HU HU0203597A patent/HU229458B1/hu unknown
- 2000-11-28 CA CA002392050A patent/CA2392050C/en not_active Expired - Lifetime
- 2000-11-28 US US10/129,773 patent/US6750237B1/en not_active Expired - Lifetime
- 2000-11-28 JP JP2001541504A patent/JP2003515559A/ja active Pending
- 2000-11-28 PT PT00979765T patent/PT1237551E/pt unknown
- 2000-11-28 WO PCT/GB2000/004528 patent/WO2001039772A1/en active IP Right Grant
2002
- 2002-05-09 IL IL149578A patent/IL149578A/en unknown
- 2002-05-09 ZA ZA200203704A patent/ZA200203704B/xx unknown
- 2002-05-24 IS IS6394A patent/IS2135B/xx unknown
- 2002-05-28 NO NO20022525A patent/NO322119B1/no not_active IP Right Cessation
- 2002-05-29 MX MXPA02005319A patent/MXPA02005319A/es active IP Right Grant
2003
- 2003-01-21 HK HK03100515.3A patent/HK1048442B/zh not_active IP Right Cessation
- 2003-01-23 HK HK03100621.4A patent/HK1048445B/zh not_active IP Right Cessation
- 2003-08-14 HK HK03105852A patent/HK1053430A1/xx not_active IP Right Cessation
2004
- 2004-05-27 US US10/854,959 patent/US7220767B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20040214899A1 (en)	2004-10-28
NZ518862A (en)	2004-02-27
SK7532002A3 (en)	2002-12-03
CZ301528B6 (cs)	2010-04-07
NO20022525D0 (no)	2002-05-28
EP1237551B1 (en)	2005-03-30
HUP0203597A3 (en)	2005-07-28
HK1048442A1 (en)	2003-04-04
ATE291914T1 (de)	2005-04-15
IL149578A (en)	2008-04-13
IL149578A0 (en)	2002-11-10
NO322119B1 (no)	2006-08-14
KR20020058051A (ko)	2002-07-12
GB2373726A (en)	2002-10-02
MXPA02005319A (es)	2002-12-06
RU2255736C2 (ru)	2005-07-10
HU229458B1 (en)	2013-12-30
EP1237551A1 (en)	2002-09-11
HK1048442B (zh)	2005-05-13
BR0016138B1 (pt)	2013-09-10
HUP0203597A2 (hu)	2003-02-28
US6750237B1 (en)	2004-06-15
PT1237551E (pt)	2005-07-29
PL357597A1 (en)	2004-07-26
ZA200203704B (en)	2003-10-29
DE60019162D1 (de)	2005-05-04
CA2392050A1 (en)	2001-06-07
DE60019162T2 (de)	2006-02-02
KR100670092B1 (ko)	2007-01-17
GB2373726B (en)	2004-10-20
HK1048445A1 (en)	2003-04-04
BR0016138A (pt)	2002-08-06
RU2002117649A (ru)	2004-01-27
AU1715701A (en)	2001-06-12
JP2003515559A (ja)	2003-05-07
IS6394A (is)	2002-05-24
GB0214845D0 (en)	2002-08-07
SK287228B6 (sk)	2010-03-08
IS2135B (is)	2006-08-15
GB9928578D0 (en)	2000-02-02
HK1048445B (zh)	2005-08-26
HK1053430A1 (en)	2003-10-24
UA75059C2 (uk)	2006-03-15
PL200679B1 (pl)	2009-01-30
CA2392050C (en)	2009-11-24
AU778092B2 (en)	2004-11-18
CN1402636A (zh)	2003-03-12
US7220767B2 (en)	2007-05-22
CN1222287C (zh)	2005-10-12
CZ20021901A3 (cs)	2002-11-13
EE05305B1 (et)	2010-06-15
WO2001039772A1 (en)	2001-06-07
ES2236001T3 (es)	2005-07-16
EE200200283A (et)	2003-06-16
BRPI0016138B8 (pt)	2021-05-25

Publication	Publication Date	Title
PT1237551E (pt)	2005-07-29	Formulacoes farmaceuticas contendo zolmitriptano
GB0005251D0 (en)	2000-04-26	Therapeutic compounds
TR199901417T2 (xx)	1999-10-21	Analjezik etkisi olan yeni bile�imler.
AU2003297260A1 (en)	2004-06-03	Fast-disintegrating solid dosage forms being not friable and comprising pullulan
ID27504A (id)	2001-04-12	Formulasi oral baru
TR199801180T2 (xx)	1998-10-21	Aneljestik etkiye sahip yeni bile�ikler.
IL144294A0 (en)	2002-05-23	P53 inhibitors and therapeutic use of the same
NO20062504L (no)	2006-07-21	Sammensetninger og doseringsformer for forbedret absorpsjon
TR200002773T2 (tr)	2001-11-21	Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
HUP0301349A2 (hu)	2003-08-28	IL-11-tartalmú készítmények
NO20004419L (no)	2000-10-20	Ny anvendelse
NO20011217D0 (no)	2001-03-09	Doseringsform omfattende væskeformulering
ATE301999T1 (de)	2005-09-15	Racecadotril enthaltende trockene pulverformulierung
RS50089B (sr)	2009-01-22	Suspenzija ziprasidona
RS49599B (sr)	2007-06-04	Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
SE0001916D0 (sv)	2000-05-23	Novel formulation
TR199801184T2 (xx)	1998-09-21	Analjezik tesirli yeni bile�ikler.
BG105984A (bg)	2002-04-30	Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ES2159479A1 (es)	2001-10-01	Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
TR200000916T2 (tr)	2000-07-21	İkameli piperidin türevleri.
ATE247976T1 (de)	2003-09-15	10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel
UA38889A (uk)	2001-05-15	Лікувальний засіб "ліварекс" на основі диметоксіуреїдофосфорної кислоти

Legal Events

Date	Code	Title	Description
2019-03-25	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: GRUENENTHAL GMBH, DE
2020-12-07	MK1K	Patent expired